Abaturov Alexandr E, Vysochyna Iryna L, Babych Veronika L, Dosenko Victor E
State Institution «Dnipropetrovsk Medical Academy of the Ministry of Health of Ukraine», Dnipro, Ukraine.
Bogomolets Institute Of Physiology of the National Academy of Sciences of Ukraine, Kyiv, Ukraine.
Wiad Lek. 2020;73(1):41-45.
The alm: To study the effect of choleretic therapy on the level of microRNA expression in functional disorders of the gallbladder and Oddi's sphincter in children.
Materials and methods: Fifty patients with functional disorders of the gallbladder and Oddi's sphincter who received standard therapy in combination with ursodeoxycholic acid, 20 patients - standard therapy without ursodeoxycholic acid, and 20 healthy children were examined. The level of expression of microRNA-378f, microRNA-4311, microRNA-4714- 3p in the blood serum by the method of real-time polymerase chain reaction with reverse transcription according to the protocol TaqMan Gene Expression Assays was performed.
Results: It was demonstrated that the activity profile of microRNA-4714-3p was significantly lower in those examined with functional disorders of the gallbladder and Oddi's sphincter than in practically healthy children (p<0.05). After standard therapy combined with ursodeoxycholic acid in children with functional disorders of the gallbladder and Oddi's sphincter, the level of expression of microRNA-378f is significantly higher than before therapy (5.23±0.70 SU and 2.02±0.57 SU respectively) (p<0.05). Against the background of standard therapy with the addition of ursodeoxycholic acid or without it, the expression profile of microRNA-4714-3p in the blood serum in children with functional disorders of the gallbladder and Oddi's sphincter significantly decreased (1.93±0.58 SU and 1,14±0,53 SU respectively) (p<0.05).
Conclusions: Ursodeoxycholic acid in children with functional disorders of the gallbladder and Oddi's sphincter affects the activity of generation of gene regulators of the cellular mechanisms of microRNA-378f and microRNA-4714-3p.
研究利胆疗法对儿童胆囊和奥迪括约肌功能紊乱时微小RNA表达水平的影响。
材料和方法：对50例接受标准疗法联合熊去氧胆酸治疗的胆囊和奥迪括约肌功能紊乱患者、20例接受不含熊去氧胆酸的标准疗法的患者以及20名健康儿童进行检查。采用实时聚合酶链反应逆转录法，按照TaqMan基因表达分析方案检测血清中微小RNA-378f、微小RNA-4311、微小RNA-4714-3p的表达水平。
结果表明，胆囊和奥迪括约肌功能紊乱患者的微小RNA-4714-3p活性谱显著低于实际健康儿童（p<0.05）。在胆囊和奥迪括约肌功能紊乱的儿童中，标准疗法联合熊去氧胆酸治疗后，微小RNA-378f的表达水平显著高于治疗前（分别为5.23±0.70 SU和2.02±0.57 SU）（p<0.05）。在标准疗法加或不加熊去氧胆酸的背景下，胆囊和奥迪括约肌功能紊乱儿童血清中微小RNA-4714-3p的表达谱显著降低（分别为1.93±0.58 SU和1.14±0.53 SU）（p<0.05）。
结论：熊去氧胆酸对胆囊和奥迪括约肌功能紊乱的儿童微小RNA-378f和微小RNA-4714-3p细胞机制的基因调节因子生成活性有影响。
